candesartan has been researched along with Pulmonary Fibrosis in 1 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Pulmonary Fibrosis: A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yin, G | 1 |
| Zhu, WY | 1 |
| Zhang, H | 1 |
| Li, YF | 1 |
| Zhang, CL | 1 |
1 other study available for candesartan and Pulmonary Fibrosis
| Article | Year |
|---|---|
[Studying the influence of Candesartan cilexetil on the lung fibrosis in rats exposed to silica].
Topics: Angiotensin II; Animals; Benzimidazoles; Biphenyl Compounds; Bronchoalveolar Lavage Fluid; Female; L | 2012 |